Rheumnow Podcast cover image

Rheumnow Podcast

Latest episodes

undefined
Jun 13, 2024 • 41min

EULAR 2024 Daily Recap - Days 1 & 2

Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey
undefined
Jun 13, 2024 • 4min

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
undefined
Jun 13, 2024 • 4min

The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis

Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
undefined
Jun 13, 2024 • 5min

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
undefined
Jun 13, 2024 • 4min

Voclosporin and Steroids in Lupus Nephritis

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.  
undefined
Jun 13, 2024 • 2min

3 Big Lupus Themes from EULAR 2024

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. 
undefined
Jun 13, 2024 • 6min

Does B Cell Depletion Matter?

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
undefined
Jun 13, 2024 • 3min

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
undefined
Jun 13, 2024 • 5min

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
undefined
Jun 13, 2024 • 5min

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app